SEATTLE, Nov. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $26,000 compared to $112,000 for the quarter ended September 30, 2007. Revenue for the nine months ended September 30, 2008 was $83,000 compared to $715,000 for the nine months ended September 30, 2007.
Dendreon's total operating expenses for the third quarter of 2008 were $17.3 million compared to $19.8 million in 2007. Dendreon's total operating expenses for the nine months ended September 30, 2008 were $55.1 million compared to $75.2 million for the same period in 2007.
The net loss for the quarter ended September 30, 2008 was $26.8 million, or $0.29 per share, compared to a net loss of $19.2 million, or $0.23 per share, for the quarter ended September 30, 2007. The net loss for the nine months ended September 30, 2008 was $62.8 million, or $0.71 per share, compared to $72.3 million, or $0.88 per share for the nine months ended September 30, 2007. Included in our net loss for the three and nine months ended September 30, 2008 was a non-cash charge of $9.1 million and $6.8 million, respectively, to other expense. This represents an increase in the fair value of the warrants issued in connection with our April 3, 2008 common stock offering, which has been recorded as a liability.
Cash, cash equivalents and short-term and long-term investments at
September 30, 2008 totaled $106.6 million compared to $120.6 million at
December 31, 2007. Additionally, subsequent to September 30, 2008, the
Company received net proceeds of $19.8 million relating to a draw down on
the Company's equity line of credit with Azimuth Opportunity Ltd.
* Completed the planned interim analysis of the Phase 3, randomized,
double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate
AdenoCarcinoma Treatment, also known as D9902B) clinical trial
designed to assess the safety and efficacy of the investigational
active cellular immunotherapy PROVENGE(R) (sipuleucel-T) in men with
metastatic androgen-independent prostate cancer. While Dendreon
remains blinded to the data, the independent data monitoring
committee (IDMC) reported to Dendreon a 20 percent reduction in the
risk of death in the PROVENGE arm relative to placebo (Hazard
Ratio= 0.80; 95% Confidence Interval [0.610-1.051]). The IDMC
observed no safety concerns and recommended that the study continue
to its final analysis, which is expected to be completed in mid-2009.
* Presented preclinical data on the Company's lead small molecule
candidate, D-3263, which targets Trp-p8 (a transmembrane cation
channel protein also known as Trp-M8), supporting Trp-p8 as a
therapeutic cancer target. Dendreon plans to file an Investigational
New Drug (IND) application later this year with the U.S. Food and
Drug Administration (FDA) to evaluate D-3263 in a Phase 1 dose
escalation study in cancer.
* Initiated a Phase 2 trial of PROVENGE called ProACT (PROstate Active
Cellular Therapy) or P07-2. The multicenter trial is enrolling 120
patients with metastatic, androgen independent prostate cancer.
* Initiated a Phase 2 trial of PROVENGE in men with localized prostate
cancer who are scheduled to undergo a radical prostatectomy. The
single-center trial called NeoACT (NEOadjuvant Active Cellular
immunoTherapy), or P07-1, which is being conducted at UCSF Helen
Diller Family Comprehensive Cancer Center, is enrolling
approximately 40 patients.
* In lieu of Dendreon's regularly scheduled quarterly conference call,
the Company will present at two upcoming investor conferences that
will be webcast. Both conferences will occur later this month and
o Rodman & Renshaw 10th Annual Healthcare Conference
o Lazard Capital Markets 5th Annual Healthcare Conference
"The interim analysis of our Phase 3 IMPACT trial was an important milestone for us. We were encouraged to see a 20 percent reduction in the risk of death in the PROVENGE arm versus placebo at the time of this analysis in a patient population that currently has few appealing treatment options available," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon Corporation. "Importantly, the results from this interim analysis are consistent with those from our previous Phase 3 studies at a similar follow-up time, and we are looking forward to the final analysis of the IMPACT trial in the middle of next year."
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
Except for historical information contained herein, this news release
contains forward-looking statements that are subject to risks and
uncertainties surrounding the efficacy of PROVENGE to treat men suffering
from prostate cancer, risks and uncertainties surrounding the presentation
of data to the FDA and approval of product applications by the FDA and
risks and uncertainties inherent in the process of discovering, developing
and commercializing drugs that are safe and effective for use as human
therapeutics. Factors that may cause such differences include risks related
to our limited operating history, risks associated with completing our
clinical trials, the risk that the safety and/or efficacy results of
existing clinical trials or from additional clinical trials for PROVENGE
will not support approval for a biologics license, the risk that the FDA
may interpret data differently than we do or require more data or a more
rigorous analysis of data than expected, the risk that the FDA will not
approve a product for which a biologics license has been applied, the risk
that the results of a clinical trial for PROVENGE or other product may not
be indicative of results obtained in a later clinical trial, risks that we
may lack the financial resources and access to capital to fund required
clinical trials or commercialization of PROVENGE, our dependence on the
efforts of third parties, and our dependence on intellectual property.
Further information on the factors and risks that could affect Dendreon's
business, financial condition and results of operations are contained in
Dendreon's public disclosure filings with the U.S. Securities and Exchange
Commission, which are available at http://www.sec.gov.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
Three months ended Nine months ended
September 30, September 30,
2008 2007 2008 2007
Revenue $26 $112 $83 $715
Research and development 12,660 13,449 39,331 54,780
General and administrative 4,625 6,364 15,720 20,458
Total operating expenses 17,285 19,813 55,051 75,238
Loss from operations (17,259) (19,701) (54,968) (74,523)
Interest income 819 2,022 2,907 4,744
Interest expense (1,218) (1,551) (3,995) (2,534)
Loss from valuation of warrant
liability (9,119) - (6,751) -
Net loss $(26,777) $(19,230) $(62,807) $(72,313)
Basic and diluted net loss per
share $(0.29) $(0.23) $(0.71) $(0.88)
Shares used in computation of basic
and diluted net loss per share 91,723 82,965 88,762 82,356
September 30, December 31,
Balance Sheet Data:
Cash and cash equivalents $61,839 $75,721
Short-term investments 35,654 27,115
Long-term investments 9,077 17,739
Total assets 145,144 161,662
Warrant liability 21,313 -
Convertible senior subordinated
notes 85,250 85,250
Total stockholders' equity 13,579 40,377
|SOURCE Dendreon Corporation|
Copyright©2008 PR Newswire.
All rights reserved